Name: UMIN ID:
Unique ID issued by UMIN | UMIN000030742 |
---|---|
Receipt number | R000035103 |
Scientific Title | Efficacy and safety of ripasudil hydrochloride in glaucoma patients being treated by prostaglandin analogues, but their intraocular pressures are 15mmHg or under. |
Date of disclosure of the study information | 2018/01/18 |
Last modified on | 2023/07/20 18:58:26 |
No. | Disposal | Last modified on | Item of update | |
---|---|---|---|---|
1 | Insert | 2018/01/10 10:05:25 | ||
2 | Update | 2018/01/10 11:16:58 | Date of protocol fixation |
|
3 | Update | 2018/01/18 09:06:43 | Public title Public title Acronym Acronym |
|
4 | Update | 2018/01/18 09:08:11 | Narrative objectives1 Basic objectives2 Primary outcomes |
|
5 | Update | 2018/01/18 09:20:14 | Basic design Control No. of arms Interventions/Control_1 Interventions/Control_1 Interventions/Control_2 Interventions/Control_2 Key inclusion criteria Key inclusion criteria |
|
6 | Update | 2018/01/18 09:21:10 | Organization |
|
7 | Update | 2018/01/18 09:22:13 | Recruitment status |
|
8 | Update | 2020/07/13 19:03:47 | Recruitment status Date of IRB Anticipated trial start date Last follow-up date |
|
9 | Update | 2020/10/13 07:12:40 | Study type Basic design Randomization Blinding Control No. of arms Purpose of intervention Type of intervention Interventions/Control_1 Interventions/Control_1 Key inclusion criteria Key inclusion criteria |
|
10 | Update | 2020/11/04 09:59:09 | Last follow-up date Other related information Other related information |
|
11 | Update | 2023/07/19 19:31:09 | Recruitment status |
|
12 | Update | 2023/07/20 17:49:51 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Last name of contact person Last name of contact person Zip code Organization Organization Address Address Tel |
|
13 | Update | 2023/07/20 18:51:06 | URL releasing protocol Publication of results URL related to results and publications Number of participants that the trial has enrolled Results Results Results date posted Baseline Characteristics Baseline Characteristics Participant flow Participant flow Adverse events Adverse events Outcome measures Outcome measures Plan to share IPD Plan to share IPD IPD sharing Plan description IPD sharing Plan description |
|
14 | Update | 2023/07/20 18:58:26 | Organization1 Address1 Tel1 Email1 Organization Organization Address Address Tel |